KOS-862: Interim Phase Ib data

In a dose-escalation Phase Ib trial in 13 patients with HER2-positive metastatic breast cancer IV KOS-862 plus Herceptin trastuzumab was well tolerated with no dose-limiting toxicities at the highest...